Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Akili Inc (AKLI)

Akili Inc (AKLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Tech Startup Founders Unite in Chicago for Candid Conversation and Insights at the Founders Roundtable Event hosted by LeadrPro

/PRNewswire/ -- Calling all Founders, entrepreneurs, and visionaries! LeadrPro invites you to join us at the upcoming Founders Roundtable event in downtown...

AKLI : 0.3925 (-1.87%)
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (“Akili”),...

PRTC : 27.89 (-2.14%)
PRTC.LN : 215.250 (+0.58%)
AKLI : 0.3925 (-1.87%)
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRx Ⓡ (AKL-T01) in...

AKLI : 0.3925 (-1.87%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 27.89 (-2.14%)
PRTC.LN : 215.250 (+0.58%)
BIIB : 216.13 (+0.61%)
KRTX : 329.83 (+0.03%)
VOR : 1.7700 (+2.91%)
AKLI : 0.3925 (-1.87%)
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11,...

AKLI : 0.3925 (-1.87%)
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress.

AKLI : 0.3925 (-1.87%)
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday,...

AKLI : 0.3925 (-1.87%)
Akili to Participate in the Cowen 43rd Annual Health Care Conference

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43 rd Annual Health Care Conference in Boston next month.

AKLI : 0.3925 (-1.87%)
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference , both happening alongside the J.P. Morgan Healthcare...

AKLI : 0.3925 (-1.87%)
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adolescents label expansion study evaluating the efficacy and safety of EndeavorRx Ⓡ...

AKLI : 0.3925 (-1.87%)

Barchart Exclusives

Down 12% from Highs, Should You Buy the Dip in This Dividend Aristocrat?
This prominent paint industry player has been raising dividends for more than four decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar